Greenphire Appoints Senior Director of Business Development in Europe
Greenphire, a leading provider of payment technologies for the clinical trials industry, has extended its presence in Europe with the appointment of Alex Livingstone. A seasoned industry executive, Alex brings more than 12 years of eClinical software, pharmaceutical and biotechnology industry experience to the company, in a move designed to help Greenphire extend its footprint in European markets.
Based in London, Alex will be responsible for developing market awareness of Greenphire's solutions and will lead the company's overall business development strategy in Europe. He joins Greenphire having previously served as Global Account Manager at Phase Forward (now Oracle), where he was charged with driving worldwide sales strategies. Previous to this role, he worked for G.D. Searle prior to its acquisition by Pfizer.
"Having admired Greenphire's achievements in the clinical payment technology field, its innovative nature and dynamic management team, I am delighted to have been chosen to lead the next stage of the company's development in Europe," comments Alex Livingstone. "I am excited to join a brand where innovation is valued and the desire to change things for the better is at the core of its strategy."
Commenting on the new appointment, Greenphire CEO Sam Whitaker said: "Alex's extensive experience in the industry will be a tremendous asset to Greenphire at a time when we are developing quickly as a business. He will play a key role in capturing commercial opportunities in key markets across Europe and I am confident Alex will be a strong asset to Greenphire and our clients alike."
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance